Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Regional variation in out-of-hospital cardiac arrest: incidence and survival - a nationwide study of regions in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The clinical use of hyperbaric oxygen in the treatment of Danish patients with diabetic foot ulcers

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVE: To examine the prevalence of drug-resistance-associated mutations in HIV patients with triple-drug class virological failure (TCF) and their association with long-term mortality. DESIGN: Population-based study from the Danish HIV Cohort Study (DHCS). METHODS: We included all patients in the DHCS who experienced TCF between January 1995 and November 2004, and we performed genotypic resistance tests for International AIDS Society (IAS)-USA primary mutations on virus from plasma samples taken around the date of TCF. We computed time to all-cause death from date of TCF. The relative risk of death according to the number of mutations and individual mutations was estimated by Cox regression analysis and adjusted for potential confounders. RESULTS: Resistance tests were done for 133 of the 179 patients who experienced TCF. The median number of resistance mutations was eight (interquartile range 2-10), and 81 (61%) patients had mutations conferring resistance towards all three major drug classes. In a regression model adjusted for CD4+ T-cell count, HIV RNA, year of TCF, age, gender and previous inferior antiretroviral therapy, harbouring > or =9 versus < or =8 mutations was associated with increased mortality (mortality rate ratio [MRR] 2.3 [95% confidence interval (CI) 1.1-4.8]), as were the individual mutations T215Y (MRR 3.4 [95% CI 1.6-7.0]), G190A/S (MRR 3.2 [95% CI 1.6-6.6]) and V82F/A/T/S (MRR 2.5 [95% CI 1.2-5.3]). CONCLUSIONS: In HIV patients with TCF, the total number of genotypic resistance mutations and specific single mutations predicted mortality.OBJECTIVE: To examine the prevalence of drug-resistance-associated mutations in HIV patients with triple-drug class virological failure (TCF) and their association with long-term mortality. DESIGN: Population-based study from the Danish HIV Cohort Study (DHCS). METHODS: We included all patients in the DHCS who experienced TCF between January 1995 and November 2004, and we performed genotypic resistance tests for International AIDS Society (IAS)-USA primary mutations on virus from plasma samples taken around the date of TCF. We computed time to all-cause death from date of TCF. The relative risk of death according to the number of mutations and individual mutations was estimated by Cox regression analysis and adjusted for potential confounders. RESULTS: Resistance tests were done for 133 of the 179 patients who experienced TCF. The median number of resistance mutations was eight (interquartile range 2-10), and 81 (61%) patients had mutations conferring resistance towards all three major drug classes. In a regression model adjusted for CD4+ T-cell count, HIV RNA, year of TCF, age, gender and previous inferior antiretroviral therapy, harbouring > or =9 versus < or =8 mutations was associated with increased mortality (mortality rate ratio [MRR] 2.3 [95% confidence interval (CI) 1.1-4.8]), as were the individual mutations T215Y (MRR 3.4 [95% CI 1.6-7.0]), G190A/S (MRR 3.2 [95% CI 1.6-6.6]) and V82F/A/T/S (MRR 2.5 [95% CI 1.2-5.3]). CONCLUSIONS: In HIV patients with TCF, the total number of genotypic resistance mutations and specific single mutations predicted mortality.
Original languageEnglish
JournalAntiviral Therapy
Volume12
Issue number6
Pages (from-to)909-17
Number of pages8
ISSN1359-6535
Publication statusPublished - 2007

    Research areas

  • Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cohort Studies, Drug Resistance, Viral, Female, Genotype, HIV, HIV Infections, Humans, Kaplan-Meiers Estimate, Male, Middle Aged, Mutation, Treatment Failure

ID: 32507004